South Asia and Beyond

‘Covaxin Phase 3 Data Looks Good’

Data from phase 3 of Bharat Biotech’s Covaxin trials looks good, says Soumaya Swaminathan, WHO chief scientist. She said the overall efficacy is high although its efficacy against the Delta variant of the Coronavirus is low. She warned of a third wave saying that the Delta variant can infect between six and eight people while the original strain infects only three people.

Related